|
|
|
4549 EIKEN CHEMICAL CO.,LTD.
|
|
| 10/30/2026 11:00 |
EIKEN CHEMICAL Selected for GHIT Fund Research and Development Project -Advancing the Development of a Rapid Diagnostic System for Ebola Virus- |
| 10/29/2026 13:00 |
Financial Results for Q2 FY2026 |
| 10/29/2026 13:00 |
Consolidated Financial Results for the Six Months Ended September 30, 2026 (Under Japanese GAAP) |
| 07/30/2026 15:30 |
Financial Results for Q1 FY2026 (April 1, 2026 to June 30, 2026) |
| 07/30/2026 15:30 |
Collaboration Agreement with TAUNS Laboratories, Inc. for the Sales of POCT Products -Strengthening Sales Channels in the Domestic Clinic Market- |
| 07/30/2026 15:30 |
Notice Regarding Introduction of Shareholder Benefits Program, etc. |
| 07/30/2026 15:30 |
Consolidated Financial Results for the Three Months Ended June 30, 2026 |
| 07/29/2026 15:30 |
Eiken Chemical Launches New Fully Automated Fecal Immunochemical Test/Fecal Calprotectin Analyzer OC-SENSOR R70 |
| 07/24/2026 16:00 |
Continues to be Selected as a Constituent of the FTSE JPX Blossom Japan Index and the FTSE JPX Blossom Japan Sector Relative Index |
| 07/22/2026 15:30 |
Notice Regarding Completion of Pay-in Procedures for Disposal of Treasury Shares as Restricted Stock Compensation |
| 06/23/2026 15:30 |
Notice Regarding Disposal of Treasury Shares as Restricted Stock Compensation |
| 06/18/2026 08:00 |
Notice Regarding Appointment of Shareholders Meeting Inspector |
| 06/04/2026 08:00 |
Notice Regarding ISS's Recommendation Report (Supporting Company Proposal / Opposing Shareholder Proposal) on Agenda Items for Our AGM |
| 06/01/2026 08:00 |
NOTICE OF CONVOCATION OF THE 88th GENERAL MEETING OF SHAREHOLDERS |
| 05/12/2026 13:00 |
Financial Results for FY2025 and Management Plan |
| 05/12/2026 13:00 |
Notice Regarding Changes to Management Plan |
| 05/12/2026 13:00 |
Notice Concerning Change in Representative Executive Officer |
| 05/12/2026 13:00 |
Notice regarding Election of Director Candidates |
| 05/12/2026 13:00 |
Consolidated Financial Results for the Fiscal Year Ended March 31, 2026 (Under Japanese GAAP) |
| 02/26/2026 15:30 |
Notice Concerning Introduction of C-Suite System and Changes in Executive Officers |
| 01/30/2026 15:30 |
Financial Results for Q3 FY2025 (April 1, 2025 to December 31, 2025) |
| 01/30/2026 15:30 |
Consolidated Financial Results for the Nine Months Ended December 31, 2025 (Under Japanese GAAP) |
| 12/15/2025 13:00 |
Selected as one of the highest rated A List companies in CDP's climate change study |
| 12/10/2025 15:00 |
In Vitro Diagnostic Products Announcement of Simultaneous Launch of Three New Kits for Malaria |
| 11/14/2025 15:30 |
Notice Concerning Completion of Cancellation of the treasury shares |
|
